Clinical Trial Update: PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer [Phase 1]

View source ↗

Summary

Phase I trial evaluating the SRC kinase inhibitor dasatinib in combination with paclitaxel and carboplatin for ovarian, peritoneal, and fallopian tube cancers. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Paraplatin (Carboplatin)
• Sprycel (dasatinib)
• Taxol (paclitaxel)

Snippet

Sponsor: AA Secord | Conditions: Ovarian Cancer, Peritoneal Cancer | Phase 1 | Status: COMPLETED